SavedAdd your journal

Journals / Haseki Tıp Bülteni / 2021 / Cilt: 59 - Sayı: 3

Drug-Associated Thrombocytopenia as a Rare and Devastating Side Effect of Octreotide in a Cirrhotic Patients: A Case Report and Current Literature Review

Onur KESKİN
Alper Tuna GÜVEN
Sabri Engin ALTINTOP
Pages
265–267
Publication Date
2022-10-17
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The case is reported in discussion with the existing 4 cases in theliterature.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Variceal bleeding is one of the most serious outcomes encountered in portal hypertension.
📊
Key Findings & Data:Naranjo adverse drug reactionprobability scale has revealed a probable relationship with 6 points.
💡
Conclusion & Impact:The case is reported in discussion with the existing 4 cases in theliterature.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Variceal bleeding is one of the most serious outcomes encountered in portal hypertension. It represents one of the leading causesof death in cirrhotic patients. Octreotide infusion is the mainstay of treatment in variceal bleeding. It shows its effects by loweringportal venous pressure. Here, we present a patient with variceal bleeding who experienced sudden thrombocytopenia after octreotideinfusion. Cessation of the octreotide therapy has resulted in a quick recovery of the platelet counts. Naranjo adverse drug reactionprobability scale has revealed a probable relationship with 6 points. The case is reported in discussion with the existing 4 cases in theliterature.

🔖

Cite This Article

KESKİN, O., GÜVEN, A. T., ALTINTOP, S. E. (2022). Drug-Associated Thrombocytopenia as a Rare and Devastating Side Effect of Octreotide in a Cirrhotic Patients: A Case Report and Current Literature Review. Haseki Tıp Bülteni, Cilt: 59 - Sayı: 3, 265–267. https://ajindex.com/articles/534978

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (10)

  1. D’Amico G, De Franchis R; Cooperative Study Group. Upper digestive bleeding in cirrhosis. Post-therapeutic outcome and prognostic indicators. Hepatology 2003;38:599-612
  2. Bañares R, Albillos A, Rincón D, et al. Endoscopic treatment versus endoscopic plus pharmacologic treatment for acute variceal bleeding: a meta-analysis. Hepatology 2002;35:609- 15
  3. Gøtzsche PC, Hróbjartsson A. Somatostatin analogues for acute bleeding oesophageal varices. Cochrane Database Syst Rev 2008;2008:CD000193
  4. Hanna WT, Maull KI. Sandostatin-induced thrombocytopenia. South Med J 1990;83:77
  5. Demirkan K, Fleckenstein JF, Self TH. Thrombocytopenia associated with octreotide. Am J Med Sci 2000;320:296-7
  6. Chisholm S, Gummadi B, Vega KJ, House J. Sandostatin causing reversible thrombocytopenia. Eur J Gastroenterol Hepatol 2009;21:474-5
  7. Rashidi A, Rizvi N. Octreotide-induced thrombocytopenia: a case report. J Med Case Rep 2011;5:286
  8. Aster RH, Bougie DW. Drug-induced immune thrombocytopenia. N Engl J Med 2007;357:580-7
  9. Christie DJ, Mullen PC, Aster RH. Fab-mediated binding of drugdependent antibodies to platelets in quinidine- and quinineinduced thrombocytopenia. J Clin Invest 1985;75:310-4
  10. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45.